<DOC>
	<DOCNO>NCT00133913</DOCNO>
	<brief_summary>This study enrol patient measurable metastatic colorectal cancer . Blood drawn prior patient receive new therapy his/her cancer subsequently 7-14 day , 3-4 week , image study do ( ~every 6 12 week ) . The blood test find circulate tumor cell ( CTCs ) count . The CTC level compare image study result see CTC number image result ( progression/no progression ) agreement . Maximum active study participation 12 month 8 blood draw take . All patient currently follow 24 month study date survival . The CTC result also use see difference survival progression-free survival patient without certain number CTCs .</brief_summary>
	<brief_title>Circulating Tumor Cells Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Measurable metastatic carcinoma colon rectum . 1st 2nd line chemotherapy ( 3rd line acceptable epidermal growth factor receptor [ EGFR ] target therapy ) Chest/abdomen/pelvis scan every 612 week ECOG 02 Hemoglobin ( Hgb ) &gt; = 8g/dl within 7 day prior enrollment Age &gt; = 18 year age Cumulative weekly blood draw exceed 150mL/week Brain metastasis Prior history carcinoma within last 5 year , except ductal carcinoma situ ( DCIS ) , noninvasive cervical cancer nonmelanoma skin cancer Surgery within 14 day initial blood draw , exclude surgical placement central venous device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
</DOC>